CURTIS J THOMPSON
Nursing at Caminito Cantilena, San Diego, CA
License number
Florida 3324152
Issued Date
Oct 12, 1998
Effective Date
Jan 1, 1901
Expiration Date
Apr 30, 2018
Category
Health Care
Type
Registered Nurse
Address
Address
2
18656 Caminito Cantilena, San Diego, CA 92128
5555 Grossmont Center Dr, La Mesa, CA 91942
5555 Grossmont Center Dr, La Mesa, CA 91942
Phone
(305) 431-7505
Professional information
Senior Director Of Pharmacology At Halozyme Therapeutics, Inc.
Position:
Senior Director of Pharmacology at Halozyme Therapeutics, Inc.
Location:
Greater San Diego Area
Industry:
Pharmaceuticals
Work:
Halozyme Therapeutics, Inc.
- Greater San Diego Area since Jan 2013
-
Senior Director of Pharmacology
Halozyme Therapeutics, Inc.
- Greater San Diego Area Jan 2010 - Dec 2012
-
Director of Pharmacology
Halozyme Therapeutics, Inc.
- Greater San Diego Area Jan 2009 - Dec 2009
-
Associate Director, Pharmacology
Halozyme Therapeutics, Inc.
- Greater San Diego Area Sep 2007 - Dec 2008
-
Group Leader, Pharmacology
Halozyme Therapeutics
- Greater San Diego Area Mar 2007 - Aug 2007
-
Senior Scientist, Research
Isis Pharmaceuticals
- Greater San Diego Area Feb 2005 - Nov 2005
-
Senior Scientist, Antisense Core Research
Isis Pharmaceuticals
- Greater San Diego Area Aug 2002 - Jan 2005
-
Senior Scientist, Antisense Drug Discovery
Isis Pharmaceuticals
- Greater San Diego Area Jan 2002 - Aug 2002
-
Postdoctoral Scientist, Antisense Research
University of California, San Diego
- Greater San Diego Area Jan 2000 - Nov 2001
-
Postdoctoral Fellow, Vascular Biology Laboratory
Education:
Keck School of Medicine of the University of Southern California 1993 - 1998
University of California, Davis 1981 - 1986
University of California, Davis 1981 - 1986
Skills:
Drug Discovery, In Vivo, Pharmacology, Biotechnology, Lifesciences, Drug Development, Assay Development, Clinical Development, IND, Animal Models, Biochemistry, Molecular Biology, Biomarkers, Translational Research, Cell Culture, ELISA, Oncology, Pharmaceutical Industry, Translational Medicine, CRO, Biomarker Discovery, Inflammation, Cell, Cancer, Regulatory Submissions
Combination Therapy With An Anti-Hyaluronan Agent And Therapeutic Agent
US Patent:
2013030, Nov 14, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/815804
Inventors:
Daniel C. Maneval - San Diego CA, US
H. Michael Shepard - San Diego CA, US
Curtis B. Thompson - San Diego CA, US
H. Michael Shepard - San Diego CA, US
Curtis B. Thompson - San Diego CA, US
International Classification:
A61K 47/48, A61K 31/56, A61K 31/7068
US Classification:
424450, 424 943, 424400, 4241781, 514 152
Abstract:
Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
Composition And Lipid Formulation Of A Hyaluronan-Degrading Enzyme And The Use Thereof For Treatment Of Benign Prostatic Hyperplasia
US Patent:
2013025, Sep 26, 2013
Filed:
Feb 19, 2013
Appl. No.:
13/815311
Inventors:
Xiaoming Li - San Diego CA, US
Mysore Ramprasad - San Diego CA, US
Curtis Thompson - San Diego CA, US
Harold Michael Shepard - San Diego CA, US
Louis Howard Bookbinder - San Diego CA, US
Gregory Ian Frost - Del Mar CA, US
Mysore Ramprasad - San Diego CA, US
Curtis Thompson - San Diego CA, US
Harold Michael Shepard - San Diego CA, US
Louis Howard Bookbinder - San Diego CA, US
Gregory Ian Frost - Del Mar CA, US
International Classification:
A61K 38/47
US Classification:
424450, 424 9462, 424 945
Abstract:
Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.